Kelingyuan

Kelingyuan is the innovative drug research and development arm of Xiling Lab (Chengdu Xilingyuan Pharmaceutical), a clinical-stage biotechnology company headquartered in Chengdu, China. The company specializes in the development of next-generation Antibody-Drug Conjugates (ADCs) using its proprietary XL-XDC technology platform, which incorporates high-potency payloads and the stabilized SuperHydra linker system. Its lead clinical candidate, SMP-656, is a HER2-targeting ADC utilizing an eribulin payload for the treatment of advanced solid tumors. Additionally, Kelingyuan is advancing SMP-100, a small molecule 5-HT3 receptor partial agonist targeting irritable bowel syndrome with diarrhea (IBS-D). The company maintains strategic collaborations with prominent firms such as 3SBio/Sunshine Guojian to accelerate the development of ADC programs. Kelingyuan operates a global R&D network with facilities in Chengdu, Shenzhen, and Australia to support its growing pipeline of targeted therapies.